Filing Flows

Filing Flows › Health Care › Kestra Medical Technologies (KMTS)

Kestra Medical Technologies (KMTS) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Sep 14, 2026 · Kestra Medical Technologies (KMTS) Q1 FY27 earnings results →

Q1 FY27 Revenue up 60% year over year to $31.0M · 142¢ of every $1 of revenue lost · operating margin -121.6%

Kestra Medical Technologies made $31.0M in Q1 FY27 (+60% Y/Y). Operating margin -121.6%, net loss $44.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Sep 14, 2026.

Revenue$31.0M
Year over year+60%
Operating margin-121.6%
Net earnings−$44.1M
Operating cash flow−$32.3M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $31.0M in Q1 FY27, up 60% year over year and up 8% from the previous quarter.

Gross margin was 56.5%, up 10.8 points from Q1 FY26. Operating costs exceeded revenue by $37.7M, an operating margin of -121.6%. Operating expenses grew 46% against revenue growth of 60%. The fastest-growing cost line was Research & development (+70%). The quarter ended with a net loss of $44.1M, wider than the previous quarter's $38.8M loss.

Operating cash flow was −$32.3M. Non-cash charges added back $2.7M of depreciation and $9.5M of share-based compensation. Capital expenditures of $8.3M exceeded it, leaving free cash flow of −$40.6M.

Quarterly history

Kestra Medical Technologies revenue by quarterKestra Medical Technologies revenue by quarter$15.1MQ3 FY25$17.2MQ4 FY25$19.4MQ1 FY26$22.6MQ2 FY26$24.6MQ3 FY26$28.6MQ4 FY26$31.0MQ1 FY27
Kestra Medical Technologies net earnings by quarterKestra Medical Technologies net earnings by quarter−$21.8MQ3 FY25−$51.1MQ4 FY25−$25.8MQ1 FY26−$32.8MQ2 FY26−$34.2MQ3 FY26−$38.8MQ4 FY26−$44.1MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QSep 14, 2026$31.0M+60%-121.6%−$44.1M−$32.3M
Q4 FY2610-KJul 14, 2026$28.6M+66%-137.4%−$38.8M−$18.7M
Q3 FY2610-QMar 17, 2026$24.6M+63%-141.6%−$34.2M−$18.4M
Q2 FY2610-QDec 11, 2025$22.6M+53%-140.7%−$32.8M−$18.3M
Q1 FY2610-QSep 12, 2025$19.4M+52%-149.1%−$25.8M−$26.3M
Q4 FY2510-KJul 17, 2025$17.2M—-279.8%−$51.1M−$24.1M
Q3 FY2510-QApr 17, 2025$15.1M—-136.5%−$21.8M−$18.0M

Charts

Kestra Medical Technologies: revenue growth, year over year and quarter over quarterKestra Medical Technologies: revenue growth, year over year and quarter over quarterY/YQ/Q+14%Q4 FY25+52%+12%Q1 FY26+53%+16%Q2 FY26+63%+9%Q3 FY26+66%+17%Q4 FY26+60%+8%Q1 FY27
Latest (Q1 FY27): Y/Y +60%, Q/Q +8%.
Kestra Medical Technologies: where the cash came from (+) and went (−), TTM to Q1 FY27Kestra Medical Technologies: where the cash came from (+) and went (−), TTM to Q1 FY27Other investing−$181MOther financing$171MCash drawn (+) / kept (−)$133MOperating cash flow−$87.7MCapital spending−$35.1M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Kestra Medical Technologies: profit against cash, quarter by quarterKestra Medical Technologies: profit against cash, quarter by quarterNet incomeOperating cash flow−$20.6M−$18.1MQ2 FY25−$21.8M−$18.0MQ3 FY25−$51.1M−$24.1MQ4 FY25−$25.8M−$26.3MQ1 FY26−$32.8M−$18.3MQ2 FY26−$34.2M−$18.4MQ3 FY26−$38.8M−$18.7MQ4 FY26−$44.1M−$32.3MQ1 FY27
Latest (Q1 FY27): Net income −$44.1M, Operating cash flow −$32.3M.
Kestra Medical Technologies: diluted shares by fiscal year (split-adjusted)Kestra Medical Technologies: diluted shares by fiscal year (split-adjusted)40MFY2449MFY2554MFY26
+36.2% since FY24: more shares outstanding (issuance, stock pay); earlier years scaled for the 2-for-1 split before FY26.
Kestra Medical Technologies in its industry: growth against margin (111 companies, SIC 3841)Kestra Medical Technologies in its industry: growth against margin (111 companies, SIC 3841)revenue growth, year over year →↑ operating marginmedian +10%median -9%MDLNMMMSYKBSXBDXBAXSOLVRMDDXCMWSTMMEDPODDGMEDTFXICUIMMSIIARTPENHAETNDMEMBCIRTCATECGKOSOFIXINSPNVCRUFPTATRCBVSAORTPRCTTCMDARAYANGOKIDSSKINLMATHTFLMDXGCERSSIBNTMCISTIMINFUBBNXOSURANIKDCTHRCELSGHTIRMDXTNTLUNGNPCEPDEXTELACARLLNSRSIMOBIAPYXSSIICVRXCLPTKRMDTLSIPROFSNWVCTSOIDXGUTMDRVPSNOAPREMNEPHDRIOVVOSBTCYNXGLMDAIMDNCPMINONE.SRTSSINTIVFNMTCNSPRAURXXAIRLUCDTNONINBSRNXTVTAKUSAQICUVYCOHRGNCNSYPLSEPETVFEMYOSRHCODXOBIORDGLPAVMGUTSKMTS (+60%, -100%)
Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Kestra Medical Technologies

Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com .

In its own words, from its 8-K, filed Sep 14, 2026.

Kestra Medical Technologies against its Surgical & Medical Instruments & Apparatus peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +60% against the peers' median +5%. Operating margin: -121.6% against the peers' median 13.3%.

CompanyQuarterRevenueY/YOp. margin
KMTS Kestra Medical TechnologiesQ1 FY27$31.0M+60%-121.6%
MDLN MedlineQ3 2026$7.9B+10%6.4%
MMM 3MQ3 2026$6.6B+1%23.7%
SYK StrykerQ3 2026$6.5B+8%15.9%
BSX Boston ScientificQ3 2026$5.1B+1%16.1%
BDX Becton DickinsonQ3 FY26$5.0B+5%13.3%
BAX Baxter InternationalQ3 2026$3.0B+5%7.6%
SOLV SolventumQ3 2026$1.9B-7%3.5%
RMD ResMedQ1 FY27$1.4B+6%32.0%

Source: Kestra Medical Technologies 10-Q on SEC EDGAR · CIK 1877184 · Surgical & Medical Instruments & Apparatus

More on KMTS

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare KMTS with

中文版：Kestra Medical Technologies（KMTS）财报

Español · Français